Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Verastem, Inc.

Get SEC filing alerts via email and in your feed for Verastem, Inc.

VSTM

Verastem, Inc.

About Verastem, Inc.

Verastem, Inc. is a biopharmaceutical company focused on developing and commercializing targeted small molecule therapies for RAS/MAPK pathway-driven cancers. Its pipeline includes RAF/MEK inhibitors, FAK inhibitors, and KRAS inhibitors, targeting solid tumors such as ovarian, lung, and pancreatic cancers. The company emphasizes innovative mechanisms, strategic partnerships, and regulatory pathways to improve treatment outcomes for patients with difficult-to-treat cancers.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Verastem, Inc.

1
1
Verastem, Inc. Verastem Reports $36.6 Million Net Loss and First Product Revenue in Q1 2026

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Verastem, Inc. Verastem Reports $30.9M Revenue from AVMAPKI FAKZYNJA CO-PACK, Faces $209.5M Net Loss

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Verastem, Inc. Verastem Reports $11.2M Product Revenue and $98.5M Net Loss in Latest Quarter

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Verastem, Inc. Verastem Reports $25.9 Million Net Loss in Q2 2025, Revenue from New Product Launch

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Verastem, Inc. Verastem Reports $52.1 Million Net Loss in Q1 2025, FDA Approves AVMAPKI FAKZYNJA

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Verastem, Inc. Verastem Reports $130.6 Million Net Loss for 2024, Highlights Regulatory Progress and Financial Concerns

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Verastem, Inc. Verastem Reports $10M Revenue, Net Loss of $66M in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments